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Background. RAS is dysregulated in neurofibromatosis type 1 (NF1) related plexiform neurofibromas (PNs). The activity of
tipifarnib, which blocks RAS signaling by inhibiting its farnesylation, was tested in children and young adults with NF1 and progres-
sive PNs.
Methods. Patients aged 3–25 years with NF1-related PNs and imaging evidence of tumor progression were randomized in a double-
blinded fashion to receive tipifarnib (200 mg/m2 orally every 12 h) or placebo (phase A) and crossed over to the opposite treatment
arm at the time of tumor progression (phase B). PN volumes were measured with MRI, and progression was defined as ≥20% volume
increase. Time to progression (TTP) in phase A was the primary endpoint, and the trial was powered to detect whether tipifarnib
doubled TTP compared with placebo. Toxicity, response, and quality of life were also monitored.
Results. Sixty-two patients were enrolled. Tipifarnib and placebo were well tolerated. On phase A, the median TTP was 10.6 months on
the placebo arm and 19.2 months on the tipifarnib arm (P¼ .12; 1-sided). Quality of life improved significantly compared with baseline
on the tipifarnib arm but not on the placebo arm. Volumetric tumor measurement detected tumor progression earlier than conven-
tional 2-dimensional (WHO) and 1-dimensional (RECIST) methods.
Conclusions. Tipifarnib was well tolerated but did not significantly prolong TTP of PNs compared with placebo. The randomized, flexible
crossover design and volumetric PN assessment provided a feasible and efficient means of assessing the efficacy of tipifarnib. The
placebo arm serves as an historical control group for phase 2 single-arm trials directed at progressive PNs.
Keywords: neurofibromatosis type 1, phase 2 trial, plexiform neurofibroma, RAS signaling, trial design.
Neurofibromatosis type 1 (NF1) is a common (1 in 2 500 indivi-
duals), autosomal-dominant tumor predisposition syndrome
that is associated with the development of tumors of the periph-
eral and central nervous systems.1 Plexiform neurofibromas (PNs)
are complex, benign nerve sheath tumors that develop in
20%–40% of individuals with NF1.1,2 These NF1-related PNs
may be congenital and grow slowly during childhood. PNs can
cause substantial morbidity such as pain, neurologic dysfunction,
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and compression of vital structures2,3 and can be fatal. A subset
of PNs undergo transformation to malignant peripheral nerve
sheath tumors (MPNSTs), which are aggressive soft tissue sarco-
mas.4,5 The only standard treatment for PNs is surgery. However,
the location, infiltrative nature, high vascularity, and size of PNs
make surgical resection challenging, and complete surgical re-
moval is usually not feasible.2,6–8
The NF1 gene product neurofibromin contains a domain with
significant homology to RAS GTPase-activating proteins that
regulate RAS activity. RAS is a GTPase that plays a central role in
cell survival, proliferation, and differentiation by transducing
responses to growth stimuli initiated by receptors on the cell sur-
face to intracellular signaling molecules.9 Neurofibromin acceler-
ates RAS-GTP hydrolysis to RAS-GDP and thus functions as a
negative regulator of RAS. Lack of functional neurofibromin in
NF1 leads to dysregulated RAS and tumorigenesis;10 inhibition
of RAS activity is therefore a rational target for NF1-related
tumors.11
Tipifarnib (R115777, Zarnestra) is an orally bioavailable, po-
tent, and selective inhibitor of farnesyltransferase (FTase) that
catalyzes the posttranslational farnesylation of a variety of cellu-
lar proteins including RAS, RHO-B, and RAC.12–14 FTase was iden-
tified as a target to block RAS signaling proteins, but the
antiproliferative effects of tipifarnib and other FTase inhibitors in
preclinical tumor models are not completely explained by inhib-
ition of RAS signaling alone.15,16
In a phase 1 trial of tipifarnib performed in children with refrac-
tory solid tumors or NF1-related inoperable PNs, the maximum
tolerated dose (MTD) was 200 mg/m2/dose every 12 h, daily×
21 days, repeated every 28 days.17 This pediatric MTD is equiva-
lent to the recommended adult fixed dose of 300 mg on the
same schedule for solid tumors.18,19 Dose-limiting toxicities of
tipifarnib in children are myelosuppression, rash, and gastrointes-
tinal toxicity, and the spectrum of toxicities is similar in children
with solid tumors and NF1. At steady state in children receiving
the MTD, FTase activity in peripheral blood mononuclear cells
was inhibited by 70% relative to baseline. No objective responses
(WHO criteria)20 were observed on the pediatric phase I trial, but
participants with NF1 (n¼ 17) received a median of 10 (range,
1–32) 28-day treatment cycles without development of cumula-
tive toxicity.
Tumor response is the traditional endpoint in phase 2 trials,
but substantial shrinkage of PNs after treatment with tipifarnib
was not felt to be a realistic therapeutic goal. PNs appear and
grow to a large size primarily during early childhood,21 and con-
trolling PN growth could prevent morbidity and mortality and po-
tentially reduce the risk of malignant transformation to an
MPNST. Therefore, time to progression (TTP), rather than response,
was the primary endpoint used to assess the activity of tipifar-
nib on this phase 2 trial. The novel, randomized, double-blinded
flexible crossover design ensured that all participants could
receive tipifarnib and that tipifarnib was continued in each parti-
cipant until objective evidence of tumor progression was docu-
mented. Participants were required to have evidence of PN
growth prior to study entry, and PN growth during the study
was monitored using sensitive tumor volume measurements,22
maximizing our ability to detect PN progression earlier and short-
ening the time to complete the trial. The design also provided a
comparison of the acute and chronic toxicities from tipifarnib to
placebo and assessed quality of life (QOL) on both arms. In
addition, TTP using volumetric tumor measurements (3D)22 on
MRI were compared with TTP using the conventional
1-dimensional (1D)23 and 2-dimensional (2D)20 solid-tumor
measurement methods.
Materials and Methods
This trial (NCT00021541) was sponsored by the National Cancer
Institute (NCI) Cancer Therapy Evaluation Program (CTEP), coordi-
nated by the NCI Pediatric Oncology Branch, and included 10 par-
ticipating sites, of which 7 enrolled participants.
Trial Design
The unknown natural history of PNs, their complex shape, and
slow and potentially erratic growth2 imposed challenges for
measuring a therapeutic effect from tipifarnib. A validated
method22 of semiautomated 3D MRI analysis of PNs was used
to sensitively measure changes in size of PNs on this trial.21,22
PN progression was defined as ≥20% increase in tumor volume
compared with baseline. To determine whether tipifarnib prolongs
TTP required a concurrent, untreated control population to assess
the natural history of PNs. For these reasons, we developed a ran-
domized, placebo-controlled, double-blinded, flexible crossover
design to determine whether tipifarnib increases TTP in patients
with progressive PNs.
Randomization Process
The random allocation sequence was randomly generated by a
computer program (written in-house) that followed specifications
created by the study statistician. To minimize chances of uncover-
ing the future randomization sequence, the study statistician spe-
cified that the study start with a block size of 4 and then switch to
block sizes of 2 after the first 16 participants were randomized.
The randomization sequence was provided on a paper list only
to the pharmacy, where the drug was prepared and delivered in
a double-blinded fashion; neither the participant nor the treating
physician was made aware of the treatment administered. Once
the participant was registered into the trial via a central registra-
tion office, which verified eligibility, the central office notified the
trial pharmacist, who selected the next randomly assigned slot
on the list and assigned it as the treatment for that specific
participant.
After central randomization to the tipifarnib armor placebo arm,
participants were followed on the first treatment (phase A) until PN
progression, at which time they were crossed over to the other
treatment arm (phase B) to receive the placebo if they originally
received tipifarnib or tipifarnib if they originally received the placebo.
Participants were monitored on the same schedule with 3D MRI
until PN progression was documented on phase B, at which time
they were removed from the study. The final MRI scan on phase
A demonstrating PN progression was used as the baseline scan
for phase B. The crossover ensured that all participants could re-
ceive tipifarnib, and crossing patients over to the other treatment
arm only after PN progression was documented (rather than at a
fixed time point) ensured that participants who benefitted from
tipifarnib continued to receive the drug.
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Patient Eligibility
Children and young adults ≥3 and ≤25 years with a clinical diag-
nosis of NF124 and unresectable, progressive PNs with the poten-
tial to cause significant morbidity3 were eligible if they met the
criteria outlined in Table 1. Patients who underwent prior surgery
for their progressive PNs were eligible provided the residual tumor
wasmeasurable. No prior medical therapy was required, as there is
no standard medical treatment for PNs. This trial was approved by
the Institutional Review Boards of the participating institutions. All
patients or their legal guardians signed an informed consent indi-
cating their understanding of the investigational nature and the
risks of this study. Written assent was obtained from children
aged 7–17 years.
Dosing Schedule
Tipifarnib/placebo was supplied by CTEP as 50 mg tablets and
administered orally at the pediatric solid tumor MTD (200 mg/
m2/dose)17 after a meal every 12 h for 21 days followed by a
7-day rest period for 28-day treatment cycles. Each participant’s
dosewas rounded to the nearest 50 mg using a dosing nomogram
based on body surface area. The AM and PM doses were identical.
Tablets could be crushed for easier consumption in young children.
At the time of crossover from phase A to phase B, there was a
2-week washout with no drug. Daily intake of tipifarnib/placebo
was documented by participants or their guardians in drug diaries,
which were reviewed with the medical team at the time of re-
sponse evaluations.
Toxicity Grading and Dose Modifications for Toxicity
Adverse events were graded according to the NCI Common Toxicity
Criteria version 2. Tipifarnib/placebo was held for grade 2 toxicities
considered possibly, probably, or definitely related to tipifarnib
treatment until resolution to grade ≤1. Tipifarnib/placebo was
held until resolution of toxicity and subsequent dose reduction
for recurrent grade 2 or for grade 3 or 4 drug-related toxicities. Tipi-
farnib/placebo was permanently discontinued for recurrent grade
≥2 toxicities after a dose reduction.
Potential effects of tipifarnib/placebo on growth were moni-
tored by comparing annualized growth velocities and weight
gain (increase in height or weight during phase A divided by dur-
ation of therapy in months, multiplied by 12) for placebo and
tipifarnib-treated participants.
Study Evaluations on Phases A and B
Participants were monitored with history and physical examin-
ation including neurologic evaluation, complete blood count
with differential, and serum electrolytes, creatinine, calcium,
magnesium, phosphorus, alanine aminotransferase, bilirubin,
prothrombin time, partial thromboplastin time, and fibrinogen
every 2 weeks during cycles 1–3 and subsequently prior to
every cycle. Urinalyses were performed prior to cycles 1, 4, 7,
and 10 and then every 6 cycles. Ophthalmological examinations
were performed prior to each treatment phase because dose-
dependent lens opacities were observed in rats after prolonged
administration of tipifarnib.12
Table 1. Trial eligibility requirements
Plexiform neurofibroma: Measurable : ≥3 cm in one dimension
Progressive: ≥20% increase in PN volume, or ≥13% increase in 2-dimensional, or ≥ 6% increase in 1-dimensional
measurement over last 2 consecutive MRI scans or within 1 year prior to trial evaluation
Histologic confirmation not required in presence of consistent radiographic and clinical findings but to be performed if
malignant transformation was considered
Performance status: ECOG 0–2
Life expectancy ≥12 months
Organ function: Recovered from prior therapy to grade ≤1 toxicity
Hematologic function: Absolute neutrophil count ≥1500/mL
Hemoglobin ≥9.0 g/dL
Platelet count ≥150 000/mL
Hepatic function: Bilirubin within normal limits except for participants with Gilbert syndrome
Alanine aminotransferase ≤2-times the upper limit of normal
Renal function: Age-adjusted normal serum creatinine
Prior treatment, last dose of: Colony stimulating factors ≥1 week
Radiation ≥6 weeks
Chemotherapy ≥4 weeks
Investigational agent .30 days
MRI imaging: Ability to undergo MRI evaluation of plexiform neurofibroma
Exclusion criteria: Ongoing hormonal-, immuno-, or chemotherapy directed at PN
.1 prior myelosuppressive chemotherapy regimen
Pregnancy or breastfeeding
Significant systemic unrelated illness
Presence of optic glioma, malignant glioma, malignant peripheral nerve sheath tumor, or other cancer requiring
treatment with chemotherapy or radiation
Inability to return for follow-up visits
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Short T1-inversion recovery MRI of up to 3 most clinically rele-
vant target PNs was performed for 3D analysis, as previously
described,22 prior to the start of cycles 1, 4, 7, and 10 and then
after every 6 cycles. All MRIs obtained were sent to the NCI for cen-
tral response evaluation. A volume increase of ≥20% in at least
one PN comparedwith baseline on phase A or phase B was defined
as progressive disease. Response evaluations were also performed
using standard solid tumor response criteria (RECIST and WHO cri-
teria) for comparison to TTP based on the 3D analysis.
Parents of participants aged 6–18 years completed the Im-
pact of Pediatric Illness (IPI) Scale25 about their child prior to
the start of cycles 1, 4, 7, and 10 and then after every 6 cycles.
The IPI Scale assesses QOL in 4 domains: adaptive behavior, emo-
tional functioning, medical/physical status, and cognitive func-
tioning. Responses to the 43 items are made on a 5-point Likert
scale (1 to 5) ranging from “not at all” to “a lot.” Higher mean
scores indicate better QOL.
Statistical Considerations
Comparison of TTP in participants receiving tipifarnib to partici-
pants receiving placebo during phase A was the primary analysis
and was used to estimate the sample size. In the absence of his-
torical data for TTP based on 3D PN measurements, we assumed
that TTP for untreated PNs would be 6 months. Thirty participants
per arm would be required to detect an increase in the median
TTP on phase A of 6 months with placebo to 12 months with tipi-
farnib with 80% power and a 1-tailed alpha¼ 0.05. Kaplan–Meier
analysis and log-rank statistics were used to compare TTP with
tipifarnib and placebo. We chose a large effect size, as only a sub-
stantial, clinically meaningful increase in the TTP on tipifarnib
would justify the chronic and prolonged administration of an ex-
perimental agent to this young population with histologically be-
nign tumors.
As onemeasure of evaluating treatment effects in participants
serving as their own control, we identified all participants who
had at least doubling of the TTP on tipifarnib or placebo during
phase A or B. In addition we performed a Kaplan–Meier analysis,
placing all participants who received treatment with placebo into
one curve and placing all those who received tipifarnib onto an-
other curve, irrespective of the treatment phase. In this analysis,
participants who received treatment in both phases are repre-
sented on both curves, and participants who received treatment
only in phase A are represented once; thus the 2 curves can be
presented for descriptive purposes but cannot be formally com-
pared because of lack of independence.
Based on more recent findings describing more rapid PN
growth in younger children as compared with older children21
and in nodular PN lesions,26 we also analyzed the effect of age
and PN type on PN growth rates (percent change in volume per
year). PN growth rates were analyzed using linear regression for
each target PN to detect change in PN growth rate as a result
of age, and paired results between phases (all participants who
received treatment on both phase A and phase B) were compared
using a 2-tailed Wilcoxon signed rank test. The growth rates of
target PNs and of nodular PN lesions were also compared with
a 2-tailed Wilcoxon signed rank test.
To evaluate for differences between the placebo and treat-
ment arm at enrollment, a Cox model was constructed contain-
ing treatment arm, age, PN type (nodular vs typical), number of
progressive PNs documented at enrollment, and number of PNs
known at enrollment.
For the QOL analysis, parent total scores for participants on
placebo were compared with scores for participants receiving tipi-
farnib on phase A over time. Repeated measures ANOVA were
conducted with one between groups (treatment) and one within
groups (time) factor. Post hoc analyses were done to further ex-
plore findings. Statistical tests were 2-tailed, and the alpha was
set at 0.05.
This trial was monitored annually by the NCI Center for Cancer
Research Data Safety and Monitoring Board. Trial data were
unblinded 1 year after enrollment was complete and the last pa-
tient had been enrolled on the trial for 1 year.
Results
Patient Characteristics
Sixty-two participants enrolled in the trial. This included 2 partici-
pants who were found to be ineligible after enrollment due to a
diagnosis of MPNSTand had to be replaced. Characteristics of the
60 eligible patients are listed in Table 2. At enrollment, themedian
age and PN volume of participants randomized to the tipifarnib
arm on phase A were slightly greater compared with participants
on the placebo arm. The median volume of target PNs was
364 mL (range, 20.5–5 573 mL). Five participants, 3 on placebo
and 2 on tipifarnib, had a distinct nodular lesion26 within a larger
PN, which was chosen as the target lesion. Forty-three partici-
pants had an ECOG performance score of zero, and 48 had not
received prior medical treatment for their PNs.
Tipifarnib/Placebo Toxicity
Tipifarnib and placebo were well tolerated over multiple cycles on
both treatment phases. With the exception of neutropenia and
skin rash, which are known tipifarnib-related toxicities, adverse
events were clinically indistinguishable from placebo. There was
no statistically significant difference in tipifarnib (555 cycles) vs
placebo (469 cycles) toxicity when considering themaximum tox-
icity grade per patient on phase A (p2¼ 0.28 exact Cochran-
Armitage trend test). No toxicities required unblinding. Most toxi-
cities were low grade and observed with similar incidence and
grade on the placebo and tipifarnib treatment arms (Table 3).
Seven participants were removed permanently from treatment
for reversible adverse events. Six participants receiving tipifarnib
were removed from treatment for grade 3 (n¼ 1) or grade 4
(n¼ 1) neutropenia, grade 2 (n¼ 1) or grade 3 (n¼ 1) rash,
grade 3 (n¼ 1) serum transaminase elevation, and grade 3 (n¼
1) hallucination. One participant receiving placebo was removed
from treatment for grade 3 neutropenia. This participant had a
prior history of intermittent neutropenia. One participant, who
developed grade 3 tipifarnib-related neutropenia, was able to tol-
erate tipifarnib at a reduced dose. No cumulative toxicities were
observed.
At enrollment, participants randomized to receive placebo had
a mean (standard deviation) height percentile for age of 27.2%
(+23.8) and weight percentile for age of 37.4% (+28), compared
with 25.9% (+29) and 42.5% (+34) for patients on tipifarnib, re-
spectively. There were no differences in linear growth rate or
weight gain for participants treated with tipifarnib versus placebo
Widemann et al.: Tipifarnib phase 2 trial in NF1 plexiform neurofibromas
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on phase A. Participants grew on average (standard deviation) 5.6
(+3.4) cm/year on placebo versus 4.8 (+3.6) cm/year on tipifarnib
(P¼ .36), and gained 3.1 (+4.0) kg/year of weight on placebo ver-
sus 3.6 (+4.2) kg/year on tipifarnib (P¼ .51).
Time to Progression and Response
The trial status at the time of unblinding of the study by the NCI
Data Safety and Monitoring Board is shown in Fig. 1A. Nine parti-
cipants remained on study with stable disease, 4 on phase A (2 on
placebo, 2 on tipifarnib) and 5 on phase B (3 on placebo, 2 on tipi-
farnib). Twenty-two participants had been removed from treat-
ment after progression on both treatment phases. Thirteen
participants were removed from the study for reasons other
than progression by 3D MRI analysis on phase A, and 16 partici-
pants were removed prior to or during phase B, with the 2 most
frequent reasons being withdrawal of consent and toxicity. Rea-
sons provided for withdrawal of consent included “study fatigue”
(n¼ 4), loss to follow-up (n¼ 2), and inability to return for follow-
up visits, start of a different therapy directed at the PN, sense that
current treatment was not working, and low adherence in one pa-
tient each. On phase A, only 5 of the 13 participants who were
removed from treatment prior to disease progression were cen-
sored prior to reaching the median time to progression (2 on pla-
cebo and 3 on tipifarnib). One patient with severe spinal cord
compression due to PN experienced clinical progression and
death after 2 cycles of treatment.
The median time to progression on phase A was 19.2 month
for tipifarnib (n¼ 31) and 10.6 months for placebo (n¼ 29),
1-tailed P¼ .12 (Fig. 1B). Tipifarnib thus did not achieve a doubling
of the TTP. On phase B, the median TTP was 13.3 months for tipi-
farnib (n¼ 22) and 14.5 months for placebo (n¼ 18), 1-tailed P¼
.14 (Fig. 1C).
The paired comparison of TTP on phase A and phase B with par-
ticipants serving as their own control demonstrated at least a
doubling in the TTP on tipifarnib compared with placebo in 6 of
40 participants who received treatment on both phases. One of
them received tipifarnib during phase A along with 5 during
phase B. Three participants experienced at least a doubling in
the TTP on placebo; all 3 received placebo on phase B and tipifarnib
on phase A. The median time to progression for all participants
who received placebo (n¼ 47) or tipifarnib (n¼ 53) irrespective
of the treatment phase was 13.0 and 18.2 months, respectively
(Fig. 1D). Forty participants received treatment with both placebo
Table 2. Clinical characteristics of 60 eligible participants on phase A
Total Placebo Tipifarnib
Participants enrolled (n) 60 29 31
Sex (M:F) 35:25 14:15 21:101
Age in years: Median (range) 8.5 (3–21.5) 8.2 (3–17.7) 9.7 (3–21.5)
ECOG performance score
0 45 24 21
1 13 4 9
2 2 1 1
Plexiform neurofibromas (PNs)
Number of PNs observed 96 52 44
Number of target PNs* 63 31 32
Volume (mL): Median (range) 364 (20.5–5 573) 316 (39.6–4 896) 572 (20.5–5 573)**
Location: target/observed
Neck & chest 15/20 9/12 6/8
Trunk & extremity 12/18 3/7 9/11
Pelvis 10/12 6/7 4/5
Face 7/8 3/3 4/5
Abdomen 4/12 2/7 2/5
Back 7/14 3/8 4/6
Head & neck 7/8 4/5 3/3
Extremity 1/4 1/3 0/1
Prior medical PN treatments
Yes/No 12/48 4/25 8/28
Methotrexate/vinblastine 6 3 3
Pirfenidone 3 1 2
Cis retinoic acid 1 – 1
Peginterferon alfa 2B 1 – 1
Thalidomide 1 – 1
*The PN chosen for volumetric MRI analysis to determine time to progression.
**The PN volume was larger in participants randomized to tipifarnib compared with placebo (P¼ .09, exact Wilcoxon rank sum test).
1There was no significant difference in sex by arm (P¼ .19 by Fisher’ exact test).
Abbreviation: PN, plexiform neurofibroma.
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Table 3. Number of participants with possibly, probably, or definitively tipifarnib- or placebo-related toxicities (worst toxicity grade per patient) during all
treatment cycles administered
Phase A Phase B
Tipifarnib (n¼ 31)
555 cycles
Placebo (n¼ 29)
469 cycles
Tipifarnib (n¼ 22)
319 cycles
Placebo (n¼ 19)
410 cycles
Toxicity grade CTCv2 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Allergy/immunology
Allergic reaction (rhinitis) 1
Blood/bone marrow
Hemoglobin 6 5 5 3
Neutropenia 5 1 2 1 2 3 1
Platelets 5 3 1 1
White blood count 12 2 4 1 6 4
Lymphopenia 4 5 3 3
Leukopenia 1 1
Cardiovascular
Hypertension 1
Chest pain 1
Edema 1 1 1
Palpitations 2
Coagulation
Prolonged PT 9 11 8 6
Prolonged PTT 10 9 8 7
Fibrinogen 5 4 2 2 1 2
Constitutional
Fatigue 6 4 1 2
Fever (no neutropenia) 1 1 1 3 3 1
Dermatology
Alopecia 1 2 1
Bruising 1
Flushing 2 1
Dry skin 1 1
Pruritus 4 1 3
Rash 2 2 4 3 3 1
Pink eye 1
Gastrointestinal
Anorexia 6 2 1 2
Constipation 3 2 1 2
Diarrhea 8 1 10 1 8 5
Nausea 13 10 8 4 1
Pharyngitis 1 1
Vomiting 12 6 1 4 4 1 1
Hemorrhage
Epistaxis 1 1 2
Hematuria 2 2
Hepatic
Increased bilirubin 2 1 2
Hypoalbuminemia 2 3 3 1
Bilirubin 1 3
Increased AST 3 1 3 1 3 1 1
Increased ALT 2 1 3 3 1 1
Metabolic/laboratory
Hyperkalemia 4 3 4
Hyperglycemia 3 1 1
Continued
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and tipifarnib and are therefore included on both curves. The
curves depict very similar progression patterns over time for both
agents for all participants who ever received each given agent.
PN growth rates were inversely related to age. PN growth
rates demonstrated more rapid growth in younger participants
(r¼20.45; P¼ .0005) (Fig. 2A and B). In the 40 participants
who received treatment on both phase A and phase B, PN growth
rates were significantly higher while participants were on phase A
(30.9% median increase in PN volume per year) compared with
phase B (18.5% median increase in PN volume per year) (P¼
.026). Nodular target lesions had a substantially faster growth
rate (61.6%median increase in lesion volume per year) compared
with other target PN (18.5% median increase in PN volume per
year) (P¼ .0031).
The Cox model containing treatment arm, age, PN type, num-
ber of progressive PNs documented at enrollment, and number of
PNs known at enrollment demonstrated that treatment (P¼ .59)
and number of progressive PNs documented at enrollment (P¼
.69) were not significant when jointly considered with the other
3 factors (each with P, .02). In a model removing the number
Table 3. Continued
Phase A Phase B
Tipifarnib (n¼ 31)
555 cycles
Placebo (n¼ 29)
469 cycles
Tipifarnib (n¼ 22)
319 cycles
Placebo (n¼ 19)
410 cycles
Toxicity grade CTCv2 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Hypermagnesia 3 4 2 1
Hypercalcemia 1 1 1
Hypokalemia 2 1 1
Hypoglycemia 4 2 4
Hypomagnesemia 2 1 1
Hyponatremia 3 2 3 1
Hypocalcemia 4 3 2 2
Hypophosphatemia 1 2
Bicarbonate 6 6 5 4
Neurology
Dizziness 2
Depression 1 2 1
Insomnia 1 2 1
Sensory neuropathy 1 1 1
Pain
Abdominal 9 9 2 6 1
Tumor pain/general 1
Headache 3 5 8 1
Myalgia 1
Neck 1
Other
Mood alteration/ anxiety/agitation 2 2
Cough 3 3 2
Muscle weakness 1
Otalgia (earache) 1
Mouth dryness 1
Personality/behavior 1
Blurred vision 1
Taste disturbance 1
Seizure 1
Hallucinations 1
Weight loss 2 2 1
Renal
Creatinine 1 2
Dysuria 1 1
Urinary urgency 1
Proteinuria 5 3 3
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time: PTT, partial thromboplastin time.
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of progressive PNs documented at enrollment, age, type of PN,
and number of PNs known at enrollment remained significantly
associated with time to progression on phase A (each P, .01),
while the treatment arm was not associated with time to pro-
gression when adjusting for these factors (P¼ .58 in the presence
of the other 3 factors).
Themedian TTP on phase A for all 60 participants (placebo and
tipifarnib arms combined) was 14.3 months using 3D measure-
ments with ≥20% increase in volume defined as progression.
Using the conventional tumor response criteria (WHO and
RECIST), the median TTP was 52.5 months for 2D measurements
with ≥25% increase in area defined as progression, and amedian
TTP was not reached for 1D measurements with ≥20% increase
in diameter defined as progression (Fig. 2C). At the time progres-
sion was determined by 3D analysis on phase A (n¼ 43), 10 par-
ticipants met criteria for progressive disease based on 2D and 1
patient based on 1D response criteria.
No meaningful decrease in PN volumes was observed. The lar-
gest decrease in PN volume was 11% in one participant.
Quality of Life
For the 35 participants (placebo n¼ 18, tipifarnib n¼ 17; none
with tumor progression through cycle 4) whose parents
completed the IPI Scale at baseline and pre-cycle 4 on phase A,
there was a significant group by time interaction (F (1,33)¼ 7.03;
P¼ .012) in which the mean total scores were no different over
time in the placebo group (3.70 to 3.68; F (1,17)¼ 0.19; P¼ .66)
but increased significantly in the tipifarnib group (3.69–3.91; F
(1,16)¼ 7.40; P¼ .015), indicating an early improvement in QOL
on tipifarnib.
For the 28 participants (placebo n¼ 12, tipifarnib n¼ 16; 7
participants with progression after cycle 4) who remained
on-study through both pre-cycle 4 and 10 on phase A and
received follow-up QOL assessments, there was a significant
main effect of time (F (1,26)¼ 7.00; P¼ .014) indicating an overall
increase in mean total scores and a borderline time by group
interaction (F (1,26)¼ 3.27; P¼ .082) suggesting slightly different
trajectories for the 2 groups over time. Post hoc analyses on the
separate groups found a nonsignificant change in mean scores in
the placebo group (3.72 to 3.74 to 3.84; F (2,22)¼ 2.44; P¼ .11)
and a significant increase in the mean scores of the tipifarnib
group (3.69 to 3.90 to 3.84; F (2,30)¼ 3.96; P¼ .03) similar to
the precycle 4 results.
Exploratory post hoc analyses of the parent IPI Scale domain
scores from baseline to pre-cycle 4 found a significant interaction
only in the domain of emotional functioning (F (1,33)¼ 7.75; P¼
.009), in which the mean domain scores over time were not
Fig. 1. (A) Trial status of eligible participants at the time of trial unblinding. (B) Progression-free survival on phase A. The median time to progression for
tipifarnib (n¼ 31) was 19.2 months and for placebo (n¼ 29) 10.6 months (1-tailed P¼ .12). Participants who were removed from study for reasons
other than progression had their follow-up censored at the times shown with tick marks. (C) Progression-free survival on phase B. The median time to
progression for tipifarnib (n¼ 22) was 13.3 months and for placebo (n¼ 18) 14.5 months (1-tailed P¼ .14). Participants who were removed from the
study for reasons other than progression had their follow-up censored at the times shown with tick marks. (D) Progression-free survival for all
participants who received placebo or tipifarnib irrespective of the treatment phase. The median time to progression for placebo (n¼ 47) was 13.0
months and for tipifarnib (n¼ 53) 18.2 months. Forty participants are represented on both curves. Participants who were removed from the study
for reasons other than progression had their follow-up censored at the times shown with tick marks.
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different in the placebo group (3.63 to 3.64; F (1,17)¼ 0.00; P¼
.94) but increased significantly in the tipifarnib group (3.37–
3.72; F (1,16)¼ 13.12; P¼ .002). Also, a borderline interaction
was found in the subdomain of cognitive functioning (F (1,33)¼
3.42; P¼ .07) with an upward nonsignificant trend in scores in the
tipifarnib group (3.55 to 3.89; F (1,16)¼ 3.71; P¼ .07) but not in
the placebo group (3.46 to 3.44; F (1,17)¼ 0.04; P¼ .83).
Discussion
The primary goal of this trial was to assess the activity of tipifarnib
in children and young adults with NF1 and progressive PNs using
TTP rather than response as the primary endpoint to assess activ-
ity. Although TTP on phase A was longer in participants rando-
mized to the tipifarnib arm (19.2 months) compared with the
placebo arm (10.6 months), the increase in TTP did not achieve
the targeted 2-doubling increase compared with placebo, and
the difference in TTP on the tipifarnib versus placebo arms was
not statistically significant. In addition, the median TTP for all par-
ticipants who received placebo (n¼ 47) or tipifarnib (n¼ 53), irre-
spective of the treatment phase, was similar with 13.0months for
placebo-treated and 18.2 months for tipifarnib-treated
participants.
The goal of the treatment on this study was to block aberrant
RAS signaling in NF1 PNs by inhibiting RAS farnesylation, which is a
posttranslational modification required for RAS activity. Subse-
quent studies have shown K-RAS signaling to be critical in
NF1-related tumors.27,28 Although tipifarnib effectively inhibits
H-RAS farnesylation, N- and K-RAS can also undergo an alternate
lipid modification (geranyl-geranylation), which circumvents the
effect of inhibiting farnesyltransferase.29 Alternative drugs that
block the RAS signaling pathway are available, and ongoing clin-
ical trials for children and young adults with NF1 and PNs are
evaluating agents that inhibit signal transduction proteins down-
stream of RAS including the multi-targeted tyrosine kinase inhibi-
tor sorafenib,30 which inhibits RAF, and AZD6244 (NCT01362803),
a specific MEK inhibitor.
An alternative explanation for the longer TTP on the tipifarnib
arm on phase A could be the older age of participants rando-
mized to receive tipifarnib on phase A. We have previously
reported that PNs grow more rapidly in younger children com-
pared with older children.21 While the ages did not differ signifi-
cantly between the groups (P. .5), it is possible that the
participants who received tipifarnib first (median age, 9.7 y)
would have more slowly progressive tumors compared with par-
ticipants randomized to receive placebo first (median age, 8.2 y).
Our matched comparison of the TTP between phase A and phase
B in participants serving as their own control supports this hy-
pothesis. Eight of the 9 participants who experienced at least a
doubling in the TTP on one of the treatment phases did so in
phase B, when they were older. In addition, participants had
more rapid PN growth rates on phase A compared with phase B
(P¼ .026). Finally, PN growth rates were age dependent, demon-
strating more rapid growth in younger participants (r¼20.45;
P¼ .0005). Age stratification should therefore be considered for
future clinical trials that use TTP as the primary endpoint.
Other factors to be considered for future trials include PN vol-
ume and presence of nodular target lesions. Participants rando-
mized to receive tipifarnib on phase A had larger PN volumes
compared with participants randomized to placebo (P¼ .09).
More PN growth is required in these larger tumors to reach
a 20% increase in PN volume, which may have contributed
to the longer TTP for tipifarnib on phase A. Five participants were
enrolled with progressive nodular target lesions arising within PNs,
which were recently described to grow more rapidly compared
with surrounding or adjacent PNs.26 We observed substantially
faster growth rates of nodular target lesions compared with
other target PNs on this trial (P¼ .0031). Nodular lesions may
therefore have to be considered separately in future trials.
To be eligible for this trial, participants must have had evidence
that their PNs were growing by 1D, 2D, or 3D MRI analysis during
the 12 months or within the last 2 consecutive MRI scans preced-
ing study enrollment. Limiting enrollment to participants with PNs
that are progressing is critical to demonstrating a drug effect on
PN growth. Monitoring PN volumes in this subset of participants
Fig. 2. (A) Examples of plexiform neurofibroma growth rate on phase A and phase B in 4 participants. The plexiform neurofibroma growth rate appears
constant within patients but variable among patients, and more rapid growth occurs in younger patients. (B) Percent change in target plexiform
neurofibromas (circles) or target nodular lesions (squares) volumes per year on phase A for participants treated with tipifarnib or placebo.
(C) Comparison of time to progression for 60 participants enrolled on phase A using 1D (RECIST, progression¼≥20% increase in sum of longest
diameters), 2D (WHO, progression¼≥25% increase in sum of products of longest perpendicular diameters), and 3D criteria (progression¼≥20%
increase in plexiform neurofibroma volume) used in this trial. Median time to progression was 14.3 months for 3D, 52.5 months for 2D, and was
not reached for 1D analysis.
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with progressing PNs provides information about the natural his-
tory of PNs. The tumor growth curves from participants on this
study and from our prior published study21 using volumetric
tumor measurements demonstrate that the PN growth rate is
relatively linear over months to years and that it is age depend-
ent, with more rapid growth during early childhood (Fig. 2A and
B). Therefore, treatment must focus on suppressing the growth
of PNs before they reach a size that causes morbidity, rather
than attempting to treat them after they have become clinically
apparent or symptomatic. This pattern of PN growth primarily
during childhood may mean that lifelong therapy to suppress
PN growth may not be necessary.
The group of participants randomized to the placebo arm will
serve as an historical control group for phase 2 trials of other new
drugs for NF1-related PNs. Subsequent trials comparing TTP to
this control armmust use the same eligibility criteria and specific-
ally must require participants to have evidence of PN growth prior
to enrollment and must recruit participants of a similar age range
to ensure that the comparison is valid. Single-arm clinical trials of
pirfenidone (NCT00076102), sirolimus (NCT00634270), and
peginterferon-alfa-2b (NCT00396019) use the placebo phase A
arm of this study as an historical control group.
TTP was measured using change in tumor volume estimated
with a validated, semiautomated method to derive tumor vol-
ume from standard MRI scans.22 Serial volumetric tumor mea-
surements are more sensitive for detecting tumor growth and
progressive disease compared with the WHO and RECIST tumor
measurement methods, as evidenced by the comparison of the
3 methods in Fig. 2C. The large size and complex, irregular
shape of PNs make it difficult to consistently measure tumor dia-
meters in serial scans, especially if the angle of the slices varies on
the axial images. Varying slice angles have less impact on volu-
metric measurements, which use all images containing tumor
to estimate the volume rather than taking measurements from
a single slice (WHO, RECIST). Although volumetric measurements
are more labor- and resource -intensive, requiring detailed quality
assurance and central response evaluation, compared with
tumor diameter measurements (RECIST), detecting tumor pro-
gression substantially earlier and completing the trial more rapid-
ly justifies the use of change in PN volume as the primary
endpoint. Volumetric MRI analysis in clinical trials for PNs limits
time of exposure to potentially inactive or toxic agents and serves
as the primary endpoint in many subsequent clinical trials direc-
ted at PNs.25,30–33
The QOL analyses on phase A demonstrated a significant early
improvement in overall scores, as rated by parents at baseline
and again at pre-cycle 4 for participants receiving tipifarnib but
not placebo. Further examination found a significant increase in
scores in the emotional domain and an upward nonsignificant
trend in the cognitive domain in the treatment group only. Al-
though the mechanism underlying this observation is not clear,
the effect of tipifarnib on QOL, and in particular on emotional
and cognitive functioning, is possible. Both animal34,35 and
human36 studies have shown that various drugs that target the
Ras/MAPK pathway, such as tipifarnib,37 may decrease
depressive-like behavior35,36 and reverse learning and memory
deficits.34,36 This biochemical pathway plays an important role
in hippocampal neurogenesis, which is involved in learning and
memory as well as the regulation of emotions38 and has been
implicated in the cognitive and behavioral phenotype of NF1
and other related genetic disorders.39 In addition, similar
improvements in the emotional and cognitive domains of QOL
were found in a very small sample of children with NF1 in a clinical
trial of sirolimus to treat PN.33 It is important to note that the cur-
rent results should be interpreted with caution due to having both
randommissing data and participants who went off study before
the pre-cycle 10 evaluation. However, having 2 separate studies
that yield similar, although preliminary, findings, raises a hypoth-
esis that should be investigated in future studies. Furthermore,
the QOL data support that tipifarnib was well tolerated and did
not have a negative effect on everyday functioning. Thus, the in-
corporation of patient-reported outcome measures into future
trials may provide added value in determining the clinical benefit
of therapies.40,41
The placebo-controlled, flexible crossover trial design allowed
all participants to receive tipifarnib and to remain on the drug if
they were potentially benefitting (ie, had no evidence of PN pro-
gression). The primary analysis compared TTP on tipifarnib with
placebo on phase A, but we also planned to compare tipifarnib
TTP with placebo TTP across phases A and B with each participant
serving as his or her own control. However, withdrawal from study
for reasons other than progression or toxicity increased over time,
and only 22 of the 60 participants completed (progressed on)
both phases of the study (Fig. 1A). Censoring prior to progres-
sion may thus have impacted this paired analysis, and our trial
demonstrates the potential difficulty of long-term continuous ad-
ministration of investigational agents for a non-life-threatening
condition.
In conclusion, tipifarnib did not significantly prolong TTP of PNs
compared with placebo. The randomized, flexible crossover de-
sign and volumetric PN assessment provided a sensitive and effi-
cient means of assessing the efficacy of a new agent. Tipifarnib
was well tolerated, which ensured that physicians and families
were unable to determine whether patients were receiving drug
or placebo. The placebo arm serves as an historical control
group for phase 2 single arm trials in progressive PNs.
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